| Revision as of 13:32, 10 January 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 469654296 of page Tiletamine for the Chem/Drugbox validation project (updated: ''). |
Latest revision as of 22:18, 8 February 2024 edit InternetArchiveBot (talk | contribs)Bots, Pending changes reviewers5,382,339 edits Rescuing 1 sources and tagging 0 as dead.) #IABot (v2.0.9.5) (VastV0idInSpace0 - 17117 |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
|
{{Infobox drug |
|
{{Drugbox |
|
|
|
| Verifiedfields = changed |
|
| verifiedrevid = 447428427 |
|
| verifiedrevid = 470610310 |
|
| IUPAC_name = 2-ethylamino-2-(2-thienyl) cyclohexanone |
|
| IUPAC_name = 2-Ethylamino-2-(2-thienyl)cyclohexanone |
|
| image = Tiletamine.svg |
|
| image = Tiletamine.svg |
|
|
| image2 = Tiletamine-ball-and-stick-model.png |
|
|
| alt2 = (S)-tiletamine |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data-->| tradename = |
|
⚫ |
| Drugs.com = {{drugs.com|international|tiletamine}} |
|
| tradename = |
|
|
⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| ⚫ |
| Drugs.com = {{drugs.com|international|tiletamine}} |
|
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
⚫ |
| pregnancy_category = |
| ⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
|
|
| legal_AU = S4 |
| ⚫ |
| pregnancy_category = |
|
|
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
|
| legal_US = ] |
|
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C --> |
|
|
⚫ |
| legal_status = |
|
| legal_US = Schedule III |
|
| ⚫ |
| legal_status = |
|
|
| routes_of_administration = ], ], ], Other |
|
| routes_of_administration = ], ], ], Other |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data-->| bioavailability = |
|
⚫ |
| protein_bound = |
|
| bioavailability = |
|
|
⚫ |
| metabolism = Liver |
| ⚫ |
| protein_bound = |
|
|
⚫ |
| elimination_half-life = |
| ⚫ |
| metabolism = Liver |
|
|
⚫ |
| excretion = Kidneys |
| ⚫ |
| elimination_half-life = |
|
| ⚫ |
| excretion = Kidneys |
|
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers-->| index2_label = HCl |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number_Ref = {{cascite|correct|CAS}} |
|
| CAS_number = |
|
| CAS_number = 14176-49-9 |
|
|
| CAS_number2_Ref = {{cascite|correct|CAS}} |
| ⚫ |
| ATC_prefix = none |
|
|
|
| CAS_number2 = 14176-50-2 |
| ⚫ |
| ATC_suffix = |
|
|
⚫ |
| UNII_Ref = {{fdacite|correct|FDA}} |
| ⚫ |
| PubChem = 26533 |
|
|
⚫ |
| UNII = 2YFC543249 |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
|
|
| UNII2_Ref = {{fdacite|correct|FDA}} |
| ⚫ |
| DrugBank = |
|
|
|
| UNII2 = 99TAQ2QWJI |
| ⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
|
⚫ |
| ATC_prefix = none |
| ⚫ |
| ChemSpiderID = 24714 |
|
|
⚫ |
| ATC_suffix = |
| ⚫ |
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
⚫ |
| PubChem = 26533 |
| ⚫ |
| UNII = 2YFC543249 |
|
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = |
| ⚫ |
| KEGG = D08596 |
|
|
⚫ |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
⚫ |
| ChemSpiderID = 24714 |
|
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
⚫ |
| KEGG = D08596 |
|
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data-->| C = 12 |
|
| C=12 | H=17 | N=1 | O=1 | S=1 |
|
| H = 17 |
|
|
| N = 1 |
|
| molecular_weight = 223.34 g/mol |
|
|
|
| O = 1 |
| ⚫ |
| smiles = O=C2C(c1sccc1)(NCC)CCCC2 |
|
|
|
| S = 1 |
|
| InChI = 1/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3 |
|
|
⚫ |
| smiles = O=C2C(c1sccc1)(NCC)CCCC2 |
|
| InChIKey = QAXBVGVYDCAVLV-UHFFFAOYAJ |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3 |
|
| StdInChI = 1S/C12H17NOS/c1-2-13-12(11-7-5-9-15-11)8-4-3-6-10(12)14/h5,7,9,13H,2-4,6,8H2,1H3 |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey = QAXBVGVYDCAVLV-UHFFFAOYSA-N |
|
| StdInChIKey = QAXBVGVYDCAVLV-UHFFFAOYSA-N |
|
}} |
|
}} |
|
|
|
|
|
'''Tiletamine''' is a ] and ] classified as an ].<ref>{{cite journal | vauthors = Klockgether T, Turski L, Schwarz M, Sontag KH, Lehmann J | title = Paradoxical convulsant action of a novel non-competitive N-methyl-D-aspartate (NMDA) antagonist, tiletamine | journal = Brain Research | volume = 461 | issue = 2 | pages = 343–348 | date = October 1988 | pmid = 2846121 | doi = 10.1016/0006-8993(88)90265-X | s2cid = 41671395 }}</ref> It is related chemically to ].<ref>{{PubChem|26533}}</ref> Tiletamine hydrochloride exists as odorless white crystals. |
|
|
|
|
|
It is used in ] in the ] product '''Telazol''' (tiletamine/], 50 mg/ml of each in 5 ml vial) as an injectable anesthetic for use in ]s and ]s.<ref name=Tiletamine>{{cite web|title=Tiletamine | work = Drugs.com |url= https://www.drugs.com/international/tiletamine.html|access-date=5 January 2012}}</ref><ref>{{cite journal | vauthors = Lin HC, Thurmon JC, Benson GJ, Tranquilli WJ | title = Telazol--a review of its pharmacology and use in veterinary medicine | journal = Journal of Veterinary Pharmacology and Therapeutics | volume = 16 | issue = 4 | pages = 383–418 | date = December 1993 | pmid = 8126757 | doi = 10.1111/j.1365-2885.1993.tb00206.x }}</ref><ref>{{cite web | work = Toxnet | publisher = U.S. National Library of Medicine | url = http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@rn+@rel+14176-49-9 | title = Tiletamine | date = 21 January 2009 }}</ref> It is sometimes used in combination with ] (Rompun) to chemically immobilize large ]s such as ]s<ref>{{cite journal | vauthors = Cattet MR, Caulkett NA, Lunn NJ | title = Anesthesia of polar bears using xylazine-zolazepam-tiletamine or zolazepam-tiletamine | journal = Journal of Wildlife Diseases | volume = 39 | issue = 3 | pages = 655–664 | date = July 2003 | pmid = 14567228 | doi = 10.7589/0090-3558-39.3.655 | doi-access = free }}</ref> and ].<ref>{{cite journal | vauthors = Caulkett NA, Cattet MR, Cantwell S, Cool N, Olsen W | title = Anesthesia of wood bison with medetomidine-zolazepam/tiletamine and xylazine-zolazepam/tiletamine combinations | journal = The Canadian Veterinary Journal | volume = 41 | issue = 1 | pages = 49–53 | date = January 2000 | pmid = 10642872 | pmc = 1476335 | doi = 10.4141/cjas61-007 }}</ref> Telazol is the only commercially available tiletamine product in the ]. It is contraindicated in patients of an ] of III or greater and in animals with CNS signs, hyperthyroidism, cardiac disease, pancreatic or renal disease, pregnancy, ], or penetrating eye injuries.<ref name=Tiletamine/> |
|
|
|
|
|
== Society and Culture == |
|
|
Recreational use of telazol has been documented.<ref>{{cite journal | vauthors = Quail MT, Weimersheimer P, Woolf AD, Magnani B | title = Abuse of telazol: an animal tranquilizer | journal = Journal of Toxicology. Clinical Toxicology | volume = 39 | issue = 4 | pages = 399–402 | year = 2001 | pmid = 11527235 | doi = 10.1081/clt-100105161 | s2cid = 21280839 }}</ref> Animal studies have also shown that tiletamine produces rewarding and reinforcing effects.<ref>{{cite journal | vauthors = de la Peña JB, Lee HC, de la Peña IC, Woo TS, Yoon SY, Lee HL, Han JS, Lee JI, Cho YJ, Shin CY, Cheong JH | display-authors = 6 | title = Rewarding and reinforcing effects of the NMDA receptor antagonist-benzodiazepine combination, Zoletil®: difference between acute and repeated exposure | journal = Behavioural Brain Research | volume = 233 | issue = 2 | pages = 434–442 | date = August 2012 | pmid = 22659394 | doi = 10.1016/j.bbr.2012.05.038 | s2cid = 25425333 }}</ref> Products that combine Tiletamine and ] are classified as ] ]s in the United States.<ref>{{cite web|title=Lists of: Scheduling Actions, Controlled Substances, Regulated Chemicals|url=http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf|publisher=Drug Enforcement Administration|access-date=5 January 2012|archive-date=17 April 2016|archive-url=https://web.archive.org/web/20160417085648/http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf|url-status=dead}}</ref> Otherwise, as noted by the ], tiletamine is unscheduled: “…ules applicable to the scheduling of tiletamine and zolazepam as individual entities are not warranted at this time. Neither tiletamine nor zolazepam, as discrete substances, is perceived to pose a significant threat to the health and general welfare at this time…”<ref>{{Cite web |date=January 21, 1987 |title=Schedules of Controlled Substances: Placement of Preparations Which Contain Both Tiletamine and Zolazepam into Schedule III |url=http://isomerdesign.com/Cdsa/FR/52FR2221.pdf |url-status=live |archive-url=https://web.archive.org/web/20220303023244/http://isomerdesign.com/Cdsa/FR/52FR2221.pdf |archive-date=March 3, 2022 |access-date=January 16, 2023 |website=Isomer Design |publisher=]}}</ref> |
|
|
|
|
|
== References == |
|
|
{{Reflist|2}} |
|
|
|
|
|
== External links == |
|
|
* |
|
|
|
|
|
{{General anesthetics}} |
|
|
{{Hallucinogens}} |
|
|
{{Ionotropic glutamate receptor modulators}} |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
] |